[Report of nationwide questionnaire: intraperitoneal chemotherapy for advanced ovarian cancer based on clinical results--reports of 5th "Gynecologic Intraperitoneal Chemotherapy Study Group" meeting].
We established the "Gynecologic Intraperitoneal Chemotherapy Study Group" in October, 1990. To date 5 annual meetings have been held during the Japanese Cancer Therapy Meeting. The members decided to establish a standard protocol of intraperitoneal chemotherapy (IP-CTX) for advanced ovarian cancer based on the clinical results obtained at each institution. Thus we first collected the clinical data from the affiliated institutes. Questionnaires concerning the indication of IP-CTX and the resulting data were sent to physicians working at 267 facilities in January, 1994. As a result, the reply rate was 28.8% (77/267). According to the results from 40 institutions, the consensus was that patients with residuum less than 0.5 cm in diameter after primary debulking surgery were suitable for IP-CTX. However, the remaining 37 institutions reported that patients with a macroscopic residuum less than 2 cm in diameter or those with bulky residuum greater than 2 cm in diameter demonstrated good responses to IP-CTX. Thus, further analyses are required to elucidate the appropriate indication and establish the standard protocol of IP-CTX for ovarian cancer in a clinical setting.